Discovery of direct-acting small molecule activators of KCC2 for drug resistant epilepsy
The DRG collaborates with AstraZeneca and the Moss Labs for Translational Science to describe small molecule activators of KCC2, which restore the activity of benzodiazepines in status epilepticus